Intramedullary Osteosarcoma Treatment Market Snapshot (2023 to 2033)
The global intramedullary osteosarcoma treatment market was anticipated to reach a valuation of US$ 489.86 Million in the year 2022. With a steady CAGR of 4.9% from 2023 to 2033, this market is expected to reach US$ 518.76 Million by 2023 and US$ 920.3 Million by 2033.
The most prevalent form of bone cancer, intramedullary osteosarcoma or osteogenic sarcoma, arises in the cells that create new bone structures. While it may affect any bone in the body, osteosarcoma most frequently affects the long bones, including those in the hands or legs. Osteosarcoma signs and symptoms include edema and localized bone discomfort. The American Society of Clinical Oncology estimated that in 2021, there were 3,610 new cases of bone cancer in the United States and 2,060 deaths from bone cancer. Such elevated incidences of osteosarcoma globally are expected to accelerate the demand for intramedullary osteosarcoma treatment during the forecast period.
Increasing public awareness is a key driver in accelerating market expansion. Other important market-driving factors include increased government support for research and development, rising demand for innovative treatments for uncommon cancers like osteosarcoma, and rising healthcare costs in some regions of the world. Acetaminophen (Paracetamol), generally known as aspirin, is a kind of pain reliever. In addition, rising emerging markets with an increasing elderly population base, soaring research and development activities in the healthcare sector, and rapidly increasing technological advancements and modernization in healthcare devices will all further create new opportunities for the intramedullary osteosarcoma market between 2023 and 2033.
Moreover, the market is anticipated to develop significantly due to a rise in government activities to raise awareness about osteosarcoma globally and an increase in the need for healthcare services. Several governmental organizations are launching campaigns to raise awareness of osteosarcoma therapy. Due to a boom in healthcare, industrial growth, and investments, developing markets in the Asia-Pacific as well as LAMEA regions provide attractive bone cancer treatment market opportunities for industry participants.
The intramedullary osteosarcoma treatment market is now dominated by North America, and this dominance is anticipated to last for a few more years. Since there are now several clinical trials for bone cancer treatments taking place in the region, mostly in the United States, it is anticipated that the region will expand its market share in the future. New chemotherapies are being tested in several studies. Researchers are also considering novel applications for the portfolio of currently authorized medicines. For instance, researchers are examining whether combining the bisphosphonate zoledronic acid (Zometa), used to fill the space left by a giant cell tumor, with the bone cement may lessen the likelihood of the tumor returning to that location. Such factors are anticipated to propel the market during the forecast period.
The market for intramedullary osteosarcoma therapy is quite competitive and has a sizable number of key companies. All of the market's current participants are either long-standing providers of therapies like radiation therapy and chemotherapy or they are putting their focus on research into cutting-edge osteosarcoma treatments like targeted therapy as well as immunotherapy. For instance, the FDA's Centers for Devices and Radiological Health designated ZetaMet technology as a groundbreaking device in December 2021 for use in the management of metastatic bone malignancies and osteologic treatments.
Data Point
Key Statistics
Expected Market value in 2023
US$ 518.76 Million
Expected Market value in 2033
US$ 920.3 Million
Growth Rate (2023 to 2033)
4.9%
Intramedullary osteosarcoma is the most common sarcoma of the bone. It is also referred to as conventional osteosarcoma. It represents about 80% of the Osteosarcoma cases mostly affecting youth between 20-25 years. Intra medullary osteosarcoma is a high-grade malignant sarcoma which arises from the center of the bone. Its prevalence is slightly higher in the male population, mostly occurring during adolescent age.
Intramedullary osteosarcoma can be further divided into osteoblastic, chondriblastic and fibroblastic osteosarcomas. Increasing levels of Serum alkaline phosphatase can be a marker for this disease. Early stage diagnosis involves X-ray and MRIs.
Computer tomography scans can help in identifying cortical irregularities, fracture sites, mineralization, and neurovascular involvement. Other scans like scintigraphy and PET scans can help identify metastasis. Further Confirmatory test like a biopsy is essential in diagnosis. The most common chemotherapy agents used for treatment are methotrexate with leucovorin, doxorubicin, cisplatin, and ifosfamide.
Etoposide can be used to treat metastatic conditions. Use of chemotherapy for intramedullary osteosarcoma has shown to increase the survival rate by five years. Post resection chemotherapy is recommended as soon as possible. Sirolimus, Everolimus are mTOR inhibitors used in treatment. Disruption of angiogenesis is another way of targeting therapy. A VEGFR, PDGFR inhibitor called Pazopanib has shown some efficacy in metastatic Osteosarcoma.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Intramedullary osteosarcoma Treatment Market: Drivers and Restraints
Intramedullary osteosarcoma is a threat to the young population worldwide, and its increasing incidences can be a driving force for the market. Research and development for discovering new treatment options for conventional osteosarcoma can act as a market driver.
Rising demand for better and novel treatment options can upswing the intramedullary osteosarcoma growth. Increasing prevalence of intramedullary osteosarcoma in young population is a major driving force for the intramedullary osteosarcoma market. Government funds for expanding research for osteosarcoma treatment can support the growth of the market. However the cost of the treatments like chemotherapy, radiation etc. can hinder the market growth.
Treatments like chemotherapy have substantial side effects on human health. This can be a cause of restraint for the market growth. A collaboration of hospitals and research labs can benefit the scope of treatment with new findings like novel immunotherapy drugs. Hospitals for In COVID-19 pandemic scenario, the valuable medical resources and treatment options being unavailable can patient’s treatment can halt or get neglected.
According to WHO, the osteosarcoma incidence rates are consistent throughout the world, while they are slightly higher in Latin America, Sudan and Uganda reporting slightly higher rates than in other regions. Increasing focus on optioning premium cancer care in developing regions can contribute majorly for the intramedullary osteosarcoma market.
Amongst all the bone cancer types, intramedullary osteosarcoma is the most common cancer and can be expected to have a large huge market size in the next decade. Various research institutions and hospital universities are undergoing research for osteosarcoma treatment.
Current treatment options available in the market are surgery, chemotherapy and radiation therapy. Collaborations of research academia and hospitals for discovering novel targets are seen to take place in the USA for intramedullary osteosarcoma treatment. Recent attractive osteosarcoma target is the mTOR pathway that stimulates proliferation, angiogenesis and survival and extensive research is going on in this are especially in USA and United Kingdom.
Find your sweet spots for generating winning opportunities in this market.
Intramedullary osteosarcoma Treatment Market: Region-wise Outlook
North America region dominates the current intramedullary osteosarcoma market as many clinical trials are undergoing in the USA for intramedullary osteosarcoma. Increasing healthcare expenditure by government in developed countries make the intramedullary osteosarcoma treatment market adoptive in these regions. Increasing prevalence rate of intramedullary osteosarcoma can be a opportunistic factor for the intramedullary osteosarcoma market growth.
Some of the market participants of intramedullary osteosarcoma treatment market are
Novartis International AG
Bristol-Myers Squibb Company
Eli Lilly and Company
Pfizer Inc.
Johnson & Johnson Services, Inc.
The research report on intramedullary osteosarcoma treatment presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data.
It also contains projections using a suitable set of assumptions and methodologies. The research report on intramedullary osteosarcoma treatment market provides analysis and information according to market segments such as geographies, application, and industry.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
The report covers exhaust analysis on
Market Segments
Market Dynamics
Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies involved
Technology
Value Chain
Regional analysis includes
North America (USA, Canada)
Latin America (Mexico. Brazil)
Western Europe (Germany, Italy, France, United Kingdom, Spain)
Eastern Europe (Poland, Russia)
Asia Pacific (India, ASEAN, Australia & New Zealand)
China
Japan
Middle East and Africa (GCC Countries, S. Africa, Northern Africa)
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.
The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
